Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Sees Significant Growth in Short Interest

Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totaling 112,375 shares, a growth of 55.8% from the March 15th total of 72,125 shares. Approximately 0.6% of the company’s shares are short sold. Based on an average daily trading volume, of 17 shares, the days-to-cover ratio is presently 6,610.3 days.

Newron Pharmaceuticals Price Performance

NWPHF remained flat at $20.00 during midday trading on Wednesday. Newron Pharmaceuticals has a 52-week low of $9.10 and a 52-week high of $20.00. The company has a fifty day simple moving average of $11.70 and a 200 day simple moving average of $10.18.

About Newron Pharmaceuticals

Newron Pharmaceuticals SpA is a clinical-stage biopharmaceutical company headquartered in Bresso, Italy, dedicated to developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts focus on small-molecule compounds designed to address unmet medical needs in neurology and psychiatry.

Newron’s lead product, safinamide, is marketed under the brand name Xadago as an adjunctive therapy for patients with mid- to late-stage Parkinson’s disease.